Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis

R. Y. Kang, J. Freire-Moar, E. Sigal, Cong-Qiu Chu

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

An inducible form of cyclooxygenase-2 (COX-2) has been shown to be upregulated in vitro by various pro-inflammatory agents, such as lipopolysaccharide, IL-1 and TNF. COX-2 appears to be responsible for the increase in prostaglandin synthesis at the site of inflammation. To examine the involvement of COX-2 in inflammation, we analysed the expression of this gene in human rheumatoid arthritis (RA) and in rat adjuvant-induced arthritis. Immunocytochemical studies of synovial membrane biopsies from human RA, osteoarthritic (OA) and normal joints using a COX-2 specific antibody showed positive staining in RA, but not in normal synovial membranes. Specifically, expression of COX-2 was detected in synovial lining cells, lymphoid aggregates and endothelial cells of blood vessels. Although some positive staining was observed in the OA joints, the number of stained cells was dramatically lower and the staining of the cells was less intense than in the rheumatoid tissue. By reverse transcription and polymerase chain reaction analysis, COX-2 mRNA was detected in the rat adjuvant arthritic limb, whereas no COX-2 mRNA was detectable in the normal limb. These observations indicate that COX-2 expression is upregulated in inflammatory joint disease and that COX-2 is a potential therapeutic target for specific inhibition.

Original languageEnglish (US)
Pages (from-to)711-718
Number of pages8
JournalBritish Journal of Rheumatology
Volume35
Issue number8
StatePublished - 1996
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Rheumatoid Arthritis
Animal Models
Experimental Arthritis
Synovial Membrane
Staining and Labeling
Extremities
Joints
Inflammation
Messenger RNA
Joint Diseases
Interleukin-1
Reverse Transcription
Prostaglandins
Blood Vessels
Lipopolysaccharides
Endothelial Cells
Cell Count
Lymphocytes
Biopsy

Keywords

  • Adjuvant-induced arthritis
  • Immunohistochemistry
  • Inflammation
  • Prostaglandin synthase
  • Rheumatoid arthritis
  • Synovial membrane

ASJC Scopus subject areas

  • Rheumatology
  • Neuroscience(all)

Cite this

Kang, R. Y., Freire-Moar, J., Sigal, E., & Chu, C-Q. (1996). Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. British Journal of Rheumatology, 35(8), 711-718.

Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. / Kang, R. Y.; Freire-Moar, J.; Sigal, E.; Chu, Cong-Qiu.

In: British Journal of Rheumatology, Vol. 35, No. 8, 1996, p. 711-718.

Research output: Contribution to journalArticle

Kang, RY, Freire-Moar, J, Sigal, E & Chu, C-Q 1996, 'Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis', British Journal of Rheumatology, vol. 35, no. 8, pp. 711-718.
Kang, R. Y. ; Freire-Moar, J. ; Sigal, E. ; Chu, Cong-Qiu. / Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. In: British Journal of Rheumatology. 1996 ; Vol. 35, No. 8. pp. 711-718.
@article{12630a0aec644a3b9b6e7a6b50458fb5,
title = "Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis",
abstract = "An inducible form of cyclooxygenase-2 (COX-2) has been shown to be upregulated in vitro by various pro-inflammatory agents, such as lipopolysaccharide, IL-1 and TNF. COX-2 appears to be responsible for the increase in prostaglandin synthesis at the site of inflammation. To examine the involvement of COX-2 in inflammation, we analysed the expression of this gene in human rheumatoid arthritis (RA) and in rat adjuvant-induced arthritis. Immunocytochemical studies of synovial membrane biopsies from human RA, osteoarthritic (OA) and normal joints using a COX-2 specific antibody showed positive staining in RA, but not in normal synovial membranes. Specifically, expression of COX-2 was detected in synovial lining cells, lymphoid aggregates and endothelial cells of blood vessels. Although some positive staining was observed in the OA joints, the number of stained cells was dramatically lower and the staining of the cells was less intense than in the rheumatoid tissue. By reverse transcription and polymerase chain reaction analysis, COX-2 mRNA was detected in the rat adjuvant arthritic limb, whereas no COX-2 mRNA was detectable in the normal limb. These observations indicate that COX-2 expression is upregulated in inflammatory joint disease and that COX-2 is a potential therapeutic target for specific inhibition.",
keywords = "Adjuvant-induced arthritis, Immunohistochemistry, Inflammation, Prostaglandin synthase, Rheumatoid arthritis, Synovial membrane",
author = "Kang, {R. Y.} and J. Freire-Moar and E. Sigal and Cong-Qiu Chu",
year = "1996",
language = "English (US)",
volume = "35",
pages = "711--718",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis

AU - Kang, R. Y.

AU - Freire-Moar, J.

AU - Sigal, E.

AU - Chu, Cong-Qiu

PY - 1996

Y1 - 1996

N2 - An inducible form of cyclooxygenase-2 (COX-2) has been shown to be upregulated in vitro by various pro-inflammatory agents, such as lipopolysaccharide, IL-1 and TNF. COX-2 appears to be responsible for the increase in prostaglandin synthesis at the site of inflammation. To examine the involvement of COX-2 in inflammation, we analysed the expression of this gene in human rheumatoid arthritis (RA) and in rat adjuvant-induced arthritis. Immunocytochemical studies of synovial membrane biopsies from human RA, osteoarthritic (OA) and normal joints using a COX-2 specific antibody showed positive staining in RA, but not in normal synovial membranes. Specifically, expression of COX-2 was detected in synovial lining cells, lymphoid aggregates and endothelial cells of blood vessels. Although some positive staining was observed in the OA joints, the number of stained cells was dramatically lower and the staining of the cells was less intense than in the rheumatoid tissue. By reverse transcription and polymerase chain reaction analysis, COX-2 mRNA was detected in the rat adjuvant arthritic limb, whereas no COX-2 mRNA was detectable in the normal limb. These observations indicate that COX-2 expression is upregulated in inflammatory joint disease and that COX-2 is a potential therapeutic target for specific inhibition.

AB - An inducible form of cyclooxygenase-2 (COX-2) has been shown to be upregulated in vitro by various pro-inflammatory agents, such as lipopolysaccharide, IL-1 and TNF. COX-2 appears to be responsible for the increase in prostaglandin synthesis at the site of inflammation. To examine the involvement of COX-2 in inflammation, we analysed the expression of this gene in human rheumatoid arthritis (RA) and in rat adjuvant-induced arthritis. Immunocytochemical studies of synovial membrane biopsies from human RA, osteoarthritic (OA) and normal joints using a COX-2 specific antibody showed positive staining in RA, but not in normal synovial membranes. Specifically, expression of COX-2 was detected in synovial lining cells, lymphoid aggregates and endothelial cells of blood vessels. Although some positive staining was observed in the OA joints, the number of stained cells was dramatically lower and the staining of the cells was less intense than in the rheumatoid tissue. By reverse transcription and polymerase chain reaction analysis, COX-2 mRNA was detected in the rat adjuvant arthritic limb, whereas no COX-2 mRNA was detectable in the normal limb. These observations indicate that COX-2 expression is upregulated in inflammatory joint disease and that COX-2 is a potential therapeutic target for specific inhibition.

KW - Adjuvant-induced arthritis

KW - Immunohistochemistry

KW - Inflammation

KW - Prostaglandin synthase

KW - Rheumatoid arthritis

KW - Synovial membrane

UR - http://www.scopus.com/inward/record.url?scp=0029785026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029785026&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 711

EP - 718

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 8

ER -